skip to main content

Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16.4 billion

The deal for Covestro is one of the biggest foreign takeovers by a Gulf state and is aimed at diluting the country's heavy dependence on oil in the energy transition
The deal for Covestro is one of the biggest foreign takeovers by a Gulf state and is aimed at diluting the country's heavy dependence on oil in the energy transition

Abu Dhabi state oil giant said it has agreed to buy German chemicals producer Covestro for €15.9 billion including debt, sending Covestro shares up 4% in early trade.

The deal represents one of the biggest foreign takeovers by a Gulf state as Abu Dhabi and other countries in the region seek to reduce their economies' heavy dependence on oil in the face of the global energy transition.

It follows protracted negotiations between the two companies and will see ADNOC pay €62 per Covestro share, equal to €14.7 billion including about €3 billion in debt.

Adnoc added it would also buy €1.17 billion worth of new shares in Covestro, a former Bayer unit, from a capital increase to improve funding of the takeover target.

The deal marks a cornerstone for ADNOC's plans to grow its petrochemicals business along with gas and renewable energy.

ADNOC has also been in talks with Austria's OMV for more than a year to merge their petrochemical joint ventures Borealis and Borouge. ADNOC took a 24.9% stake in OMV from Abu Dhabi sovereign fund Mubadala in February.

Covestro, which makes plastics and chemicals for the automotive, construction and engineering sectors, was created in 2015 after being spun off from Bayer. It opened its books to ADNOC in June - a year after ADNOC's initial interest was reported.

Covestro reported a net loss of €72m in the first six months of the year, compared with €46m profit in the previous year.

The agreement illustrates an increase in dealmaking between the Middle East and Europe, as Gulf investors are drawn to company valuations that lag those in the US, an easier regulatory backdrop for buyers from the region, and where investment needs make them more welcome, advisers and analysts have told Reuters.

It is the Middle East's second biggest acquisition after Israel's Teva Pharmaceuticals move to buy Allergan's generic drugs business for around $40 billion in 2015, according to Dealogic data.